Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Sarcoma, Myeloid 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Ganglioneuroblastoma 1Blast Crisis 1

Interventions

Cytarabine 5Whole-Body Irradiation 3Specimen Handling 3Injections 3CPX-351 3Blood Specimen Collection 3venetoclax 2luspatercept 2ivosidenib 2fludarabine phosphate 2fludarabine 2decitabine and cedazuridine drug combination 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Liposomes 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Filgrastim 2Daunorubicin 2Cyclosporine 2Cyclophosphamide 2Busulfan 2Biopsy 2Azacitidine 2tocilizumab 1selinexor 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Razoxane × 30 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡